abstract |
The present invention relates to new combinations of antitumour or anticancer agents for the tumour combination therapy, pharmaceutical compositions intended for combined use and kit containing compositions of different antitumour agents for combined use. In particular the present invention relates to combinations of various tumour agents with the PBK-Class I inhibitor 5-(7-methanesulfonyl-2-morpholin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrimidin-2-il-amine or pharmaceutically acceptable salts thereof. |